Santhera Pharmaceuticals Holding AG (SWX:SANN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 241.29M +31.8% |
| Revenue (ttm) | 77.19M +97.3% |
| Net Income | -49.24M |
| EPS | -3.78 |
| Shares Out | 13.95M |
| PE Ratio | n/a |
| Forward PE | 192.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 152,397 |
| Average Volume | 119,411 |
| Open | 17.20 |
| Previous Close | 17.30 |
| Day's Range | 16.86 - 18.18 |
| 52-Week Range | 9.38 - 18.84 |
| Beta | -0.34 |
| RSI | 56.34 |
| Earnings Date | Apr 28, 2026 |
About SWX:SANN
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG ... [Read more]
Financial Performance
In 2025, SWX:SANN's revenue was 77.19 million, an increase of 97.32% compared to the previous year's 39.12 million. Losses were -49.24 million, 17.3% more than in 2024.
Financial StatementsNews
Santhera Pharmaceuticals Holding AG (SPHDF) Full Year 2025 Earnings Call Highlights: Revenue ...
Santhera Pharmaceuticals Holding AG (SPHDF) Full Year 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansions Amid Challenges
Full Year 2025 Santhera Pharmaceuticals Holding AG Earnings Call Transcript
Full Year 2025 Santhera Pharmaceuticals Holding AG Earnings Call Transcript
Santhera Pharmaceuticals Holding AG Earnings Call Transcript: H2 2025
2025 saw strong revenue growth, global expansion, and robust AGAMREE uptake, with key launches in Europe and the US, improved manufacturing, and positive long-term clinical data. Guidance for 2026 remains optimistic, with breakeven expected in Q3 and new executive leadership set for transition.
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 28, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT.
Santhera Moves Closer To Earlier Treatment Access For Young DMD Patients In Europe
(RTTNews) - Santhera Pharmaceuticals (SANN) has received a positive opinion from the European Medicines Agency's CHMP to expand the use of AGAMREE (vamorolone) to children with Duchenne muscular dystr...
Santhera Pharmaceuticals Holding AG Earnings Call Transcript: H1 2025
AGAMREE achieved rapid market penetration in key regions, driving a 70% revenue increase to CHF 24 million in H1 2025. Expanded financing supports inventory for surging demand, especially in China and the US, while full-year revenue guidance was raised above CHF 65–70 million.
Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
Pratteln, Switzerland , 29 August , 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE®...
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
Pratteln, Switzerland , 19 August , 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the ...
Santhera price target raised to CHF 30 from CHF 25 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Santhera Pharmaceuticals (SPHDF) to CHF 30 from CHF 25 and keeps a Buy rating on the shares. Santhera remains engaged in various
Santhera Pharmaceuticals Holding AG Earnings Call Transcript: H2 2024
AGAMREE achieved rapid market penetration in Europe and the U.S., driving CHF 39.1 million in 2024 revenue, with strong growth expected as launches expand and manufacturing scales. Cash runway extends to mid-2026, with break-even targeted and no further fundraising planned.
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fun...
Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
Pratteln, Switzerland, January 6, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vam...
Santhera Pharmaceuticals Holding AG Earnings Call Transcript: H1 2024
Agamree's rapid uptake in Europe and the U.S. drove a 269% revenue increase year-over-year, with strong market share gains and expanded direct commercialization. Cash runway now extends into 2026, with break-even targeted that year and CHF 150 million European revenue guidance reaffirmed.
Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe
Pratteln, Switzerland, September 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive distribution agreement with GENESIS Pharma for AGAMREE® (vamorolone) for the trea...